A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

BDC Laboratories Introduces Software to Simplify Complex GOA Determination for Prosthetic Heart Valves

Statys® GOA makes it possible to perform quantitative GOA analysis

Statys® GOA software

Biomedical Device Consultants and Laboratories (BDC Laboratories) introduced its Statys® GOA software today at MD&M West. This equipment-agnostic program simplifies and automates geometric orifice area (GOA) analysis in prosthetic heart valves.

GOA analysis is a multi-dimensional imaging challenge because heart valve substitutes have complex geometries and perform nuanced movements. Statys® GOA is the first purpose-built software for quantitative comparison of heart valve leaflet opening area between hydrodynamic testing and accelerated wear testing. It’s designed to help engineering teams better comply with ISO 5840.

Learn more about the software here: https://www.bdclabs.com/testing-equipment/statys-goa-software/

Analyzes Videos and Still Images

Statys® GOA automatically analyzes video and still images, overlays boundaries, and determines the GOA for each frame, making analysis efficient, accurate, and simple. Image contrast is crucial in GOA analysis because, without clear differentiation between the leaflet edges and the background, it’s challenging to achieve accurate measurements using edge detection. With multiple algorithms for tailoring analysis and correcting image quality, it’s easy to fix less-than-ideal lighting conditions that traditionally confound these measurements.

With an intuitive interface and automated report generation, it’s easy for anyone on the team to keep track of test results and avoid knowledge transfer gaps.

A Proven Path to GOA Analysis

“This software takes an esoteric, complex measurement and simplifies it,” said Craig Weinberg, PhD, Chief Technology Officer, BDC Laboratories. “It’s a very purpose-developed software. Statys® GOA does one thing really well—and that’s quantifying the opening area of a valve throughout the cardiac cycle.”

Today, some engineering teams create their own GOA analysis algorithms in general-purpose software platforms. With Statys® GOA, BDC Laboratories is leveraging decades of experience to ensure efficient and insightful GOA analysis, even for teams with limited resources.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy